| Description | 1. Dehydrocorydaline (13-Methylpalmatine) exerts anti-metastatic potential via suppression of MMPs and Bcl-2 signaling in NSC-LC cells. 2. Dehydrocorydaline stimulates p38 MAPK activation, which can enhance heterodimerization of MyoD and E proteins, thus resulting in MyoD activation and myoblast differentiation. 3. Dehydrocorydaline shows antiplatelet effects, it inhibits thrombin-induced platelet aggregation in a low dose ( IC50= 34.914 ug/mL). 4. Dehydrocorydaline has anti-inflammatory and antinociceptive effects. 5. Dehydrocorydaline inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP. |
| Target activity | Platelet:34.914 ug/mL |
| Synonyms | Dehydrocorydalin, 脱氢紫堇碱, 13-Methylpalmatine |
| molecular weight | 366.43 |
| Molecular formula | C22H24NO4 |
| CAS | 30045-16-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 66 mg/mL(180.1 mM) Chloroform, Dichloromethane, Ethyl Acetate, Acetone, etc.: Soluble |
| References | 1. Lee J , Sohn E J , Yoon S W , et al. Anti-Metastatic Effect of Dehydrocorydaline on H1299 Non-Small Cell Lung Carcinoma Cells via Inhibition of Matrix Metalloproteinases and B Cell Lymphoma 2[J]. Phytotherapy Research, 2017, 31(3):441-448. |